by The oncology molecular diagnostic market would grow at a CAGR of 12.20% over the predicted time frame. The market is expected to increase in value from US$ 2.45 billion in 2023 to US$ 7.71 billion by 2033.
Key Takeaways
- North America contributed more than 41% of the market share in 2023.
- Asia-Pacific is estimated to expand the fastest CAGR between 2024 and 2033.
- By type, the breast cancer segment generated over 22% of the market share in 2023.
- By type, the liver cancer segment is anticipated to grow at a remarkable CAGR of 13.9% between 2024 and 2033.
- By technology, the polymerase chain reaction (PCR) segment generated over 32% of the market share in 2023.
- By technology, the sequencing segment is expected to expand at the fastest CAGR over the projected period.
- By product, the reagents segment generated over 59% of market share in 2023.
- By product, the instruments segment is expected to expand at the fastest CAGR over the projected period.
The on oncology molecular diagnostic Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/3677
A recent report provides crucial insights along with application based and forecast information in the Global Oncology molecular diagnostic Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Oncology molecular diagnostic market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Oncology Molecular Diagnostic Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 12.20% |
| Global Market Size in 2023 | USD 2.45 Billion |
| Global Market Size by 2033 | USD 7.71 Billion |
| U.S. Market Size in 2023 | USD 0.70 Billion |
| U.S. Market Size by 2033 | USD 2.25 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type, By Technology and By Product |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read Also: Emergency Department Information System Market Size, Trend Report 2032
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Oncology molecular diagnostic market are included as given below:
Oncology Molecular Diagnostic Market Companies
- Roche Diagnostics
- Abbott Laboratories
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Qiagen N.V.
- Bio-Rad Laboratories, Inc.
- Genomic Health, Inc.
- Myriad Genetics, Inc.
- Agilent Technologies, Inc.
- Siemens Healthineers
- Danaher Corporation (Cepheid)
- Sysmex Corporation
- Hologic, Inc.
- Guardant Health, Inc.
- Foundation Medicine, Inc.
Segments Covered in the Report:
By Type
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Cervical Cancer
- Liver Cancer
- Lung Cancer
- Blood Cancer
- Kidney Cancer
- Other Cancer
By Technology
- PCR
- In Situ Hybridization
- INAAT
- Chips and Microarrays
- Mass Spectrometry
- Sequencing
- TMA
- Others
By Product
- Instruments
- Reagents
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Report Objectives
- To define, describe, and forecast the global oncology molecular diagnostic market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the oncology molecular diagnostic market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Oncology Molecular Diagnostic Market
5.1. COVID-19 Landscape: Oncology Molecular Diagnostic Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Oncology Molecular Diagnostic Market, By Type
8.1. Oncology Molecular Diagnostic Market Revenue and Volume, by Type, 2024-2033
8.1.1 Breast Cancer
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Prostate Cancer
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Colorectal Cancer
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
8.1.4. Cervical Cancer
8.1.4.1. Market Revenue and Volume Forecast (2021-2033)
8.1.5. Liver Cancer
8.1.5.1. Market Revenue and Volume Forecast (2021-2033)
8.1.6. Lung Cancer
8.1.6.1. Market Revenue and Volume Forecast (2021-2033)
8.1.7. Lung Cancer
8.1.7.1. Market Revenue and Volume Forecast (2021-2033)
8.1.8. Blood Cancer
8.1.8.1. Market Revenue and Volume Forecast (2021-2033)
8.1.9. Kidney Cancer
8.1.9.1. Market Revenue and Volume Forecast (2021-2033)
8.1.10. Other Cancer
8.1.10.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Oncology Molecular Diagnostic Market, By February
9.1. Oncology Molecular Diagnostic Market Revenue and Volume, by February, 2024-2033
9.1.1. Cathode
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Anode
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Electrolyte
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
9.1.4. Separator
9.1.4.1. Market Revenue and Volume Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Oncology Molecular Diagnostic Market, By March
10.1. Oncology Molecular Diagnostic Market Revenue and Volume, by March, 2024-2033
10.1.1. Consumer
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Automotive
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. Industrial
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
10.1.4. Cheese
10.1.4.1. Market Revenue and Volume Forecast (2021-2033)
10.1.5. Others
10.1.5.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Oncology Molecular Diagnostic Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by March (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by February (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by March (2021-2033)
Chapter 12. Company Profiles
12.1. Roche Diagnostics
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Abbott Laboratories
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Thermo Fisher Scientific Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Illumina, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Qiagen N.V.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bio-Rad Laboratories, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Genomic Health, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Myriad Genetics, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Agilent Technologies, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Siemens Healthineers
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
